TMDX TransMedics Group, Inc.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Medical technology company providing OCS platform and NOP services to improve organ transplant therapy for heart, lung, and liver
• • New emphasis on NOP expansion with acquisition of Summit Aviation and 22 fixed-wing aircraft to enhance national organ transportation logistics
• • Strategic pivot toward integrating comprehensive transplant logistics, including owning aircraft, to become a full-service U.S. organ procurement provider
• • Revenue growth to $605.5M in 2025, up 37.1% YoY; total employees 898 worldwide, mostly U.S.-based
• • Commenced transition to new corporate headquarters in Somerville, MA, to support expansion and operations consolidation by 2028

Risk Factors

• • Leverage risk from $460M Notes issued May 2023, 1.50% interest, maturing June 2028
• • Macroeconomic exposure to long-term Somerville lease, $23.9M annual base rent starting 2028, escalating 2-3% annually
• • Supply chain risk from $4.0M noncancellable manufacturing purchase commitment through 2029
• • Competitive risk from reliance on sales of organ-specific disposable OCS Perfusion Sets and Consoles amid evolving organ transplant tech
• • Operational risk in international expansion with $42.9M spent on fixed-wing aircraft for transplant logistics in 2025

Management Discussion & Analysis

• • No revenue or profitability data disclosed in this section
• • Convertible Senior Notes issued $460M, net proceeds $393.3M after $52.1M capped call costs and $14.6M issuance costs, interest 1.50%
• • CIBC credit facility borrowings $60M, interest rate min 3.5% to 4.0% plus spreads, repayment starting July 2026, maturity July 2027
• • Cash expected to fund operations, capex, debt service for 12+ months; potential future capital raises may be needed
• • Risks include capacity expansion, regulatory approvals, reimbursement, competition, operating cost increases, and new product development

What are the latest TMDX SEC filings in 2026?

TransMedics Group, Inc. (TMDX) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 5, 2026, an 8-K current report on August 4, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did TMDX file its most recent 10-K annual report?

TransMedics Group, Inc. (TMDX) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view TMDX 10-Q quarterly reports?

TransMedics Group, Inc. (TMDX)'s most recent 10-Q quarterly report was filed on May 5, 2026. SignalX displays every TMDX 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has TMDX filed recently?

TransMedics Group, Inc. (TMDX)'s most recent 8-K was filed on August 4, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find TMDX insider trading activity (Form 4)?

SignalX aggregates every TMDX Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does TMDX file with the SEC?

TransMedics Group, Inc. (TMDX) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new TMDX filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for TransMedics Group, Inc. (TMDX).

What is TMDX's SEC CIK number?

TransMedics Group, Inc. (TMDX)'s SEC CIK (Central Index Key) number is 1756262. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1756262 to look up all TMDX filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find TMDX return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from TransMedics Group, Inc. (TMDX) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.